You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

ALTRENO Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Altreno patents expire, and when can generic versions of Altreno launch?

Altreno is a drug marketed by Dow Pharm and is included in one NDA. There are two patents protecting this drug.

This drug has eight patent family members in eight countries.

The generic ingredient in ALTRENO is tretinoin. There are twenty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the tretinoin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Altreno

A generic version of ALTRENO was approved as tretinoin by PADAGIS US on December 24th, 1998.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ALTRENO?
  • What are the global sales for ALTRENO?
  • What is Average Wholesale Price for ALTRENO?
Summary for ALTRENO
International Patents:8
US Patents:2
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 141
Clinical Trials: 2
Drug Prices: Drug price information for ALTRENO
What excipients (inactive ingredients) are in ALTRENO?ALTRENO excipients list
DailyMed Link:ALTRENO at DailyMed
Drug patent expirations by year for ALTRENO
Drug Prices for ALTRENO

See drug prices for ALTRENO

Recent Clinical Trials for ALTRENO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Beth Israel Deaconess Medical CenterPhase 4
Ortho DermatologicsPhase 4
Goldman, Butterwick, Fitzpatrick and GroffPhase 4

See all ALTRENO clinical trials

Pharmacology for ALTRENO
Drug ClassRetinoid

US Patents and Regulatory Information for ALTRENO

ALTRENO is protected by two US patents.

Patents protecting ALTRENO

Topical pharmaceutical compositions for treating skin conditions
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 9 YEARS OF AGE AND OLDER

Topical pharmaceutical compositions for treating skin conditions
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 9 YEARS OF AGE AND OLDER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dow Pharm ALTRENO tretinoin LOTION;TOPICAL 209353-001 Aug 23, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Dow Pharm ALTRENO tretinoin LOTION;TOPICAL 209353-001 Aug 23, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ALTRENO

See the table below for patents covering ALTRENO around the world.

Country Patent Number Title Estimated Expiration
South Korea 20030057526 ⤷  Sign Up
European Patent Office 2052714 Systemes de gel topiques destines au traitement des troubles de la peau (Topical gel delivery systems for treating skin disorders) ⤷  Sign Up
South Korea 20080036246 ⤷  Sign Up
China 1460013 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ALTRENO

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0617614 11/2001 Austria ⤷  Sign Up PRODUCT NAME: ALITRETINOIN; REGISTRATION NO/DATE: EU/1/00/149/001 20001011
1304992 132013902214376 Italy ⤷  Sign Up PRODUCT NAME: CLINDAMICINA FOSFATO E TRETINOINA(ACNATAC); AUTHORISATION NUMBER(S) AND DATE(S): PA1332/043/001, 20130322;042056010/M - 022/M, 20130718
1304992 PA2013025 Lithuania ⤷  Sign Up PRODUCT NAME: CLINFAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
1304992 SPC/GB13/061 United Kingdom ⤷  Sign Up PRODUCT NAME: CLINDAMYCIN PHOSPHATE IN COMBINATION WITH TRETINOIN.; REGISTERED: IE PA1332/043/001 20130322; UK PL15142/0249 20130624
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.